Abstract
Synapse loss occurs early and correlates with cognitive decline in Alzheimer’s disease (AD). Synaptotoxicity is driven, at least in part, by amyloid-beta oligomers (Aβo), but the exact synaptic components targeted by Aβo remain to be identified. We here tested the hypotheses that the post-synaptic protein Neuroligin-1 (NLGN1) is affected early in the process of neurodegeneration in the hippocampus, and specifically by Aβo, and that it can modulate Aβo toxicity. We found that hippocampal NLGN1 was decreased in patients with AD in comparison to patients with mild cognitive impairment and control subjects. Female 3xTg-AD mice also showed a decreased NLGN1 level in the hippocampus at an early age (i.e., 4 months). We observed that chronic hippocampal Aβo injections initially increased the expression of one specific Nlgn1 transcript, which was followed by a clear decrease. Lastly, the absence of NLGN1 decreased neuronal counts in the dentate gyrus, which was not the case in wild-type animals, and worsens impairment in spatial learning following chronic hippocampal Aβo injections. Our findings support that NLGN1 is impacted early during neurodegenerative processes, and that Aβo contributes to this effect. Moreover, our results suggest that the presence of NLGN1 favors the cognitive prognosis during Aβo-driven neurodegeneration.
Document Type
Article
Publication Date
4-24-2020
Digital Object Identifier (DOI)
https://doi.org/10.1038/s41598-020-63255-6
Funding Information
This work was supported by grants from the Fonds de recherche du Québec -Santé (FRQS), the Natural Sciences and Engineering Research Council of Canada (RGPIN-2016-05504) and the Hôpital du Sacré-Coeur de Montréal (Recherche CIUSSS-NIM) to J.B.; by a grant from the Canadian Institutes of Health Research (231095-111021) and the Canada Research Chair in Sleep Molecular Physiology held by V.M.; by a grant from the National Institutes of Health (P30AG028383) to the Alzheimer's Disease Center of the University of Kentucky; by a FRQS Junior 1 Research Scholar (33204) to J.B.; by a FRQS Senior Research Scholar (253895) to F.C.; by fellowships from the Hôpital du Sacré-Coeur de Montréal and the Department of Pharmacology of the Université de Montréal awarded to J.D.G.; and by a fellowship of the Faculty of Medicine of the Université de Montréal to L.C.
Repository Citation
Dufort-Gervais, Julien; Provost, Chloé; Charbonneau, Laurence; Norris, Christopher M.; Calon, Frédéric; Mongrain, Valérie; and Brouillette, Jonathan, "Neuroligin-1 Is Altered in the Hippocampus of Alzheimer's Disease Patients and Mouse Models, and Modulates the Toxicity of Amyloid-Beta Oligomers" (2020). Pharmacology and Nutritional Sciences Faculty Publications. 98.
https://uknowledge.uky.edu/pharmacol_facpub/98
Supplementary Fig. 1 to 8.
Included in
Medical Pharmacology Commons, Medical Physiology Commons, Neuroscience and Neurobiology Commons
Notes/Citation Information
Published in Scientific Reports, v. 10, issue 1, article no. 6956.
© The Author(s) 2020
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.